Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

Kansas Organizations Sign Nationwide Petition Regarding Access To Condoms In CVS Stores
The Kansas City Star on Sunday examined a national petition -- signed recently by several local organizations -- requesting that CVS Caremark unlock condoms in all of its CVS pharmacy stores. "The petition, sponsored by the labor coalition Change to Win, said CVS stores tended to lock up condoms, especially in low-income neighborhoods with high numbers of minorities," the Star reports. CVS has said the practice is "a defense against shoplifters in stores where large numbers of condoms were stolen," according to the Star. CVS spokesperson Mike DeAngelis said not all condoms are locked in display cases. "DeAngelis also said the group behind the condom petition ò€¦ was mounting a smear campaign against CVS because of a labor dispute," the article states (Erickson, 7/12).
buy viagra
Three More Sentenced In Fake Drugs Conspiracy Trial, UK
The seventh and final member of a multi-million pound international counterfeit gang was sentenced at Kingston Crown Court earlier this week, 6 July 2009.
plan for health
News of the day
With A Doctor's Help Obese Women With PCOS Can Lose Weight
Simple weight-loss advice from a physician and regular follow-up helped obese women with polycystic ovary syndrome lose a substantial amount of weight, a new study found. The results were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
Nutrition

UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®. "Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases," said Jeffrey H. Buchalter, Enzon"s chairman and chief executive officer. About CIMZIA® Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn"s disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderate to severely active rheumatoid arthritis. Cimzia® was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn"s disease who have not responded adequately to conventional treatment in September 2007. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A. Enzon Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009